Occupational Therapists in Bella Vista, AR Accepting Medicare
6 Occupational Therapists found. Showing 1 - 6
 Gloria Jean Pense, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 19 Billingsley Dr, Bella Vista, AR 72714 Phone: 479-220-0756 |
 Mr. Nolan W Barton, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9 Cunningham Cor, Bella Vista, AR 72714 Phone: 479-751-7122 Fax: 479-751-7292 |
 Child's Play Therapy Services, Inc. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 19 Billingsley Dr, Bella Vista, AR 72714 Phone: 479-220-0756 |
Jaclyn Lee Lantz, COTA/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 24 Kentallen Ln, Bella Vista, AR 72715 Phone: 479-531-3797 |
Amanda Lynn Messmer Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3 Banbury Ln, Bella Vista, AR 72714 Phone: 479-420-4312 |
Emily Millard, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2 Marlin Ln, Bella Vista, AR 72715 Phone: 417-389-4108 |
News Archive
Endra Life Sciences launches Nexus 128 preclinical photoacoustic CT scanner
Endra Life Sciences today announced the launch of the Nexus 128, a preclinical photoacoustic computed tomography (CT) scanner for small animal imaging. The system is used for simple, fast, non-invasive quantification of tumor vasculature and other physiological parameters for preclinical research.
‘Flesh-eating' disease treatments: an interview with Dr. John Crew, Seton Medical Center
Untreated, the mortality probably exceeds 70%. Flesh eating is a description of Toxic Inflammatory Cellulitis which usually starts by bacterial subcutaneous infection followed by freezing in phase II healing which is inflammatory.
Integral Molecular receives NIH contract for $5.5 million to advance vaccine discovery
The National Institute of Allergy and Infectious Diseases has awarded Integral Molecular a contract (75N93019C00073) which will provide up to $5.5M over the next five years to define antibody responses to pathogenic viruses including Zika, Marburg and equine encephalitis viruses, aiding the discovery of vaccines and therapeutics against these currently untreatable and often lethal viruses.
RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer
Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.
› Verified 4 days ago
Physical Therapists
Chiropractors
Audiologists
Speech-Language Pathologists
Occupational Therapists
Optometrists